Phenotypes associated with this allele
Allelic
Composition |
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
|
|
Genetic
Background |
involves: 129S4/SvJaeSor * 129S6/SvEv * C57BL/6 |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Scgb1a1tm1(cre/ERT)Blh mutation
(1 available);
any
Scgb1a1 mutation
(26 available)
|
|
|
normal phenotype
|
|
• mice are viable and fertile
|
mortality/aging
|
|
• animal succumb due to tumor burden at 20-24 weeks
|
neoplasm
|
|
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
|
|
|
• develop in alveoli and near the bronchioalveolar duct junction by 15 weeks of age with tamoxifen administration at 6-8 weeks
• larger bronchioles and non terminal bronchi appear normal
• advanced papillary adenocarcinomas are observed at 21 weeks after tamoxifen treatment
|
respiratory system
|
|
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
|
|
|
• hyperplasia is observed at 3 weeks after tamoxifen induction, and persists at 15 and 21 weeks
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Scgb1a1tm1(cre/ERT)Blh mutation
(1 available);
any
Scgb1a1 mutation
(26 available)
|
|
|
respiratory system
|
|
• at 12 to 34 weeks of tamoxifen treatment, 50% of mice exhibit well-defined adenocarcinomas unlike wild-type control mice
|
|
|
• after 6 weeks of tamoxifen treatment, mice exhibit bronchial epithelial hyperplasia unlike wild-type control mice
|
neoplasm
|
|
• at 12 to 34 weeks of tamoxifen treatment, 50% of mice exhibit well-defined adenocarcinomas unlike wild-type control mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Scgb1a1tm1(cre/ERT)Blh mutation
(1 available);
any
Scgb1a1 mutation
(26 available)
|
|
|
respiratory system
|
|
• after 13 weeks of tamoxifen treatment, mice exhibit bronchial epithelial hyperplasia unlike wild-type control mice
• however, areas of hyperplasia do not progress to cancer after 18 weeks of tamoxifen treatment
|
neoplasm
|
N |
• areas of hyperplasia do not progress to cancer after 18 weeks of tamoxifen treatment
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bpifa1tm1.1Jpst mutation
(0 available);
any
Bpifa1 mutation
(24 available)
Scgb1a1tm1(cre/ERT)Blh mutation
(1 available);
any
Scgb1a1 mutation
(26 available)
|
|
|
immune system
|
|
• when infected intranasally with Influenza A virus (IAV X-31), mice exhibit significantly higher virus titers than control mice at day 7 p.i.
|
|
|
• when infected intranasally with Influenza A virus (IAV X-31)
|
mortality/aging
|
|
• when infected intranasally with Influenza A virus (IAV X-31)
|
Analysis Tools